Kymera Therapeutics (KYMR) announced the presentation of new preclinical data for KT-579, its potent, selective, oral IRF5 degrader, demonstrating disease-modifying activity across multiple immuno-inflammatory diseases. The findings show that by selectively targeting and degrading IRF5, a master regulator of immune responses, KT-579 offers a novel oral approach to suppress multiple pro-inflammatory pathways implicated in diseases such as lupus and rheumatoid arthritis. These data were presented at the American College of Rheumatology, ACR, Convergence Annual Meeting being held October 24-29, 2025, in Chicago, IL.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on KYMR:
- Citi places ‘upside 90-day catalyst watch’ Kymera into data
- Nurix Therapeutics price target lowered to $21 from $22 at Wells Fargo
- Kymera Therapeutics price target raised to $75 from $59 at BTIG
- Kymera Therapeutics initiated with an Outperform at Mizuho
- Kymera Therapeutics price target raised to $80 from $60 at Citi